OncoMed Announces Early Clinical Data for anti-TIGIT Antibody
Phase 1a Dose-Escalation Data Demonstrates a Favorable Safety Profile and Signals of Immune Cell Modulation in Patients with Late Stage […]
Phase 1a Dose-Escalation Data Demonstrates a Favorable Safety Profile and Signals of Immune Cell Modulation in Patients with Late Stage […]
SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 09, 2018 (GLOBE NEWSWIRE) — Immune Design (Nasdaq: IMDZ), an immunotherapy company focused […]
Company to release financial results on Wednesday, November 14, 2016 after market close and host conference call on Friday, November […]
LOS ANGELES, Nov. 09, 2018 (GLOBE NEWSWIRE) — Motorcar Parts of America, Inc. (Nasdaq: MPAA) today announced the company will […]
*Results from full 24 weeks of dosing from the first three cohorts of the ongoing Phase 2 ACHIEVE trial in […]
MEDFORD, N.Y., Nov. 09, 2018 (GLOBE NEWSWIRE) — Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leader in point-of-care diagnostic tests for […]
Antigen Seeding Technology (AST) is a Potent and Complimentary Addition to Company’s Engineered Toxin Bodies (ETB) Technology AUSTIN, Texas, Nov. […]
RESEARCH TRIANGLE PARK, N.C., Nov. 09, 2018 (GLOBE NEWSWIRE) — Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company […]
WALTHAM, Mass. and VIENNA, Austria, Nov. 09, 2018 (GLOBE NEWSWIRE) — Arsanis, Inc. (NASDAQ: ASNS), a clinical-stage biopharmaceutical company focused […]
Preclinical Data Presented at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting Shows Highly Specific Inhibitor of TGFβ1, SRTβ1-Ab3, […]